Hacker News Reader

Bringing new drugs to markets is expensive:

https://en.wikipedia.org/wiki/Cost_of_drug_development

(These costs include the other 90% of drugs that have probably failed at some development stage)

So assuming Gilead spent per drug 10% more than the company that spent more in that list, they recovered the whole development cost in a single year. Most industries don't come even close to that.

Drugs that have an impact like their Hep C treatment don't come around every year, or even every decade. It's almost a lottery.

Welcome to capitalism, where its never enough to please shareholders and we require unlimited growth on a limited world.

Their hepC treatment is $84,000. And also somehow not profitable enough.

There is also now a $300 generic.